title: [Cervical ripening at term. A randomized and prospective study: Misoprotol versus dinoprostone].
abstract: OBJECTIVE
  To compare the efficacy and safety of cervical ripening at term by vaginal Misoprostol and Dinoprostone.
  
  
  METHODS
  We performed a prospective randomized study on cervical ripening with misoprostol and dinoprostone in the third trimester of pregnancy. 300 patients have been divided into two groups: one consisted by 150 patients who received Misoprostol (Cytotec ®) and the second consisted by 150 patients who received Dinoprostone (Prépidil ®).
  
  
  RESULTS
  Analysis of our results allowed to reveal: a significant decrease in the time of entry into work for the Misoprostol group (9.08 hours versus 12.51 hours, p = 0.007), a significant reduction delivery time (14.48 hours versus 19.30 hours, p = 0.001). Moreover, the birth rate in the first 24 hours after the first dose was significantly higher in the Misoprostol group (86.7% versus 72.7%, p = 0.003). The use of oxytocin was significantly reduced with Misoprostol (44% versus 58.7%, p = 0.01). The mode of delivery was not influenced by membership in one or other of the two groups.
  
  
  CONCLUSIONS
  Misoprostol seems an interesting molecule for cervical ripening and labor induction.
authors.affiliation: Service de Gynécologie Obstétrique - CHU Hedi Chaker, Sfax Université de Sfax.
authors.forename: Haikel
authors.initials: H
authors.lastname: Trabelsi
authors.forename: Nabil
authors.initials: N
authors.lastname: Mathlouthi
authors.forename: Sonia
authors.initials: S
authors.lastname: Zayen
authors.forename: Mohamed
authors.initials: M
authors.lastname: Dhouib
authors.forename: Kaies
authors.initials: K
authors.lastname: Chaabene
authors.forename: Khaled
authors.initials: K
authors.lastname: Trabelsi
authors.forename: Habib
authors.initials: H
authors.lastname: Amouri
authors.forename: Belhassen
authors.initials: B
authors.lastname: Ben Ayed
authors.forename: Mohamed
authors.initials: M
authors.lastname: Guermazi
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D020070:Cervical Ripening / Q000187:drug effects* / Q000502:physiology; D015232:Dinoprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007751:Labor, Induced / Q000009:adverse effects / Q000379:methods; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007744:Obstetric Labor Complications / Q000139:chemically induced / Q000453:epidemiology; D010120:Oxytocics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology / Q000628:therapy; D047929:Term Birth / Q000187:drug effects
chemical_list: D010120:Oxytocics; D016595:Misoprostol; D015232:Dinoprostone